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ABSTRACT
Objectives: We assessed the situation of academic
publications on access to and use of medicines (ATM) in
low-income and middle-income countries (LMICs) of the
Eastern Mediterranean Region (EMR). We aimed to
inform priority setting for research on ATM in the region.
Design: Bibliographic review of published studies.
Setting: LMICs in EMR.
Inclusion criteria: Publications on ATM issues
originating from or focusing on EMR LMICs covering the
period 2000–2011. Publications involving multinational
studies were included if at least one eligible country had
been included in the study.
Information sources and data extraction:We
conducted comprehensive searches of the PubMed,
Social Science Citation Index and Science Citation
Index. We used the WHO ATM framework for data
extraction and synthesis. We analysed the data
according to the ATM issues, health system levels, year
of publication and the countries of origin or focus of the
studies.
Results: 151 articles met the inclusion criteria. Most
articles (77%) originated from LMICs in EMR,
suggesting that the majority of evidence on ATM in the
region is home-grown. Over 60% of articles were from
Iran, Pakistan, Jordan and Lebanon (in order of
volume), while we found no studies assessing ATM in
Somalia, Djibouti and South Sudan, all low-income
countries. Most studies focused on the rational use of
medicines, while affordability and financing received
limited attention. There was a steady growth over time
in the number of ATM publications in the region
(r=0.87).
Conclusions: There is a growing trend, over the years,
of more studies from the region appearing in
international journals. There is a need for further
research on the financing and affordability aspects of
ATM in the region. Cross-border issues and the roles of
non-health sectors in access to medicines in the region
have not been explored widely.
INTRODUCTION
The provision of reliable access to affordable,
appropriate and high-quality medicines is a key
component of a functioning health system.1
According to the WHO Framework for Access
To and appropriate use of Medicines (ATM),
access has been deﬁned as having four para-
meters: that the available medicines are effect-
ive, of consistently good quality and are used
rationally (rational use), that there is no ﬁnan-
cial obstacle to a patient receiving it (afford-
ability), that the ﬁnancing mechanisms are
sustainable to ensure that access to quality
medicines and affordability are ensured over
time (sustainable ﬁnancing), and that the
health system provides the required infrastruc-
ture, knowledge and guidance for proper use
of medicines (health system and availability).
The Framework stipulates that any isolated
efforts on one ATM aspect would not result in
adequate and lasting improvement in the ATM
situation.2
ARTICLE SUMMARY
Strengths and limitations of this study
▪ This is the first study conducted in this region
that has collated Access To and appropriate use
of Medicines (ATM)-related published literature
to identify research priorities.
▪ We conducted systematic searches of the main
international databases for identifying ATM
articles.
▪ Although we followed rigorous methods, the search
should not be considered exhaustive. Further studies
might have been published in locally indexed or
non-indexed journals, which might not have been
captured by our methods.
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Unfortunately, ATM is often poor in low-income and
middle-income countries (LMICs). WHO estimated that
about one-third of the world’s population had limited
access to the medicines they needed. Many factors deter-
mine access. They include, for example, tax and tariff pol-
icies, pricing and affordability of medicines, price mark-up
policies, cost-sharing and copayment for medicines, and
healthcare regulation policies and ﬁnancial protection
systems for healthcare users. WHO estimates that, on
average, the availability of essential drugs in LMICs is 35%
in the public sector facilities and 66% in the private
sector.3 The quality of pharmaceutical products and the
rational use of medicines (RUMs) also affect the effective-
ness of the medicines and health outcomes.4 In many
LMICs, there is limited access to information that might
help clinical decision-making on the use of medicines.5 6
Medicines account for a high proportion of health
spending in LMICs, between 20% and 60% (compared
with an average of around 18% in high-income countries).7
Moreover, more than half of the expenditure on medicines
in most LMICs is out of the pocket.8 This inequitable ﬁnan-
cing situation, whether due to a lack of effective general
revenue ﬁnancing or social insurance ﬁnancing or other
mechanisms, creates signiﬁcant access barriers for the poor
and may lead to catastrophic household expenditures. The
poor and other population groups often rely on the private
informal sector for medicines, particularly in rural areas.
Overprescribing and inappropriate prescribing and dis-
pensing of medicines are prevalent.9
Despite some progress in some areas—such as price and
availability7—data on ATM are often weak. Even where
data are available, there is often limited systematic research
that enables the interpretation of the data and using it in
identifying priorities and developing policy options to
improve access to medicines in LMICs. The application of
health systems research tools and methods in the ﬁeld of
access to medicines will help in understanding the weak-
nesses and barriers of access to medicines and generating
useful evidence to formulate policies.10
This study was part of the ATM Policy Research
project, funded by the WHO Alliance for Health Policy
and Systems Research with the ultimate goal of “increas-
ing access to and improve the use of medicines in low
and middle income countries, particularly for the poor
(Millennium Development Goal no. 8)”.
We aimed to assess the situation of academic publica-
tions on ATM in LIMCs in the Eastern Mediterranean
Region (EMR), and the distribution of such publications
in terms of geographical coverage and issues of interest.
The ultimate objective of the study was to inform prior-
ity setting for research in the area of access to medicines
in the region and globally.
METHODS
Study design
We conducted a bibliographic review of research in EMR,
involving comprehensive searches of the literature.
The study involved an extensive search of the national,
regional and international literature in the EMR’s
LMICs in 2000–2011 and mapping of research to iden-
tify the geographical and research gaps that may not
have been covered in previous research.
Literature searches
EMR included 16 LMICs according to the World Bank
categories which comprised the geographical focus of
the study. The country-speciﬁc searches were conducted
both in relation to author afﬁliations as well as the titles
and abstracts of the articles.
A set of speciﬁc ATM terms were developed in two
brainstorming meetings and used to devise the search
strategy. The initial search strategy was tested in a number
of limited searches and was compared with a list of previ-
ously known publications. The results of the assessment
were used to ﬁnalise the search strategy (box 1). The
Box 1 Search strategy for regional literature
PubMed example:
#1- ((((((((((((((((Iran[Affiliation]) OR Pakistan[Affiliation]) OR
Lebanon[Affiliation]) OR Egypt[Affiliation]) OR Afghanistan
[Affiliation]) OR Sudan[Affiliation]) OR Yemen[Affiliation]) OR
Jordan[Affiliation]) OR Tunisia[Affiliation]) OR Morocco
[Affiliation]) OR Syria[Affiliation]) OR Palestine[Affiliation]) OR
Iraq [Affiliation]) OR Djibouti[Affiliation]) OR Libya$[Affiliation])
OR Somalia[Affiliation])
#2- (((((((((((((((((((middle east[Title/Abstract]) OR Iran[Title/
Abstract]) OR low income countries[Title/Abstract]) OR middle
income countries[Title/Abstract]) OR Pakistan[Title/Abstract])
OR Lebanon[Title/Abstract]) OR Egypt[Title/Abstract]) OR
Afghanistan[Title/Abstract]) OR Sudan[Title/Abstract]) OR
Yemen[Title/Abstract]) OR Jordan[Title/Abstract]) OR Tunisia
[Title/Abstract]) OR Morocco[Title/Abstract]) OR EMRO[Title/
Abstract]) OR Syria[Title/Abstract]) OR Palestine[Title/Abstract])
OR eastern Mediterranean[Title/Abstract]) OR Iraq [Title/
Abstract]) OR Djibouti[Title/Abstract]) OR Libya$[Title/
Abstract]) OR Somalia[Title/Abstract])
#3- (#1) OR (#2)
#4- ((((drug$[Title/Abstract]) OR medicines[Title/Abstract]) OR
medication$[Title/Abstract]) OR pharmac$[Title/Abstract])
#5- ((((((((((((((((((use[Title/Abstract]) OR access[Title/Abstract])
OR available[Title/Abstract]) OR availability[Title/Abstract]) OR
affordable[Title/Abstract]) OR affordability[Title/Abstract]) OR
utilisation[Title/Abstract]) OR utilization[Title/Abstract]) OR
essential [Title/Abstract]) OR counterfeit$[Title/Abstract]) OR
price[Title/Abstract]) OR pricing[Title/Abstract]) OR licensing
[Title/Abstract]) OR licencing[Title/Abstract]) OR labeling[Title/
Abstract]) OR labelling[Title/Abstract]) OR formularies[Title/
Abstract]) OR generic[Title/Abstract])
#6- ((((((((prescription$ [Title/Abstract]) OR prescrib$ [Title/
Abstract]) OR "drug policy"[Title/Abstract]) OR "pharmaceutical
policy"[Title/Abstract]) OR formulary[Title/Abstract]) OR phar-
macy[Title/Abstract]) OR pharmacies[Title/Abstract]) OR
pharmacist$[Title/Abstract])
#7- (#3) AND (#6)
#8- (#3) AND (#4) AND (#5)
#9- (#7) OR (#8)
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main terms selected for this study included drugs, medi-
cines, medications and pharmaceuticals and their varia-
tions. These were suitably linked with ATM-related terms.
We conducted comprehensive searches of three major
electronic databases (PubMed, Social Science Citation
Index and Science Citation Index). Initial searches were
conducted in January 2011 and all the searches were
updated in June 2011 (ﬁgure 1). Additionally, we
searched the WHO websites and contacted a few topic
experts for additional publications.
Inclusion process and criteria
Articles published from 2000 onwards were considered.
To ensure accuracy, two separate samples of 100 titles
were reviewed by two researchers and disagreements were
discussed and clariﬁed. All the remaining titles and the
abstracts of the identiﬁed articles via the search were ini-
tially reviewed by one author. After the initial screenings,
the abstracts (and subsequently the full text articles) were
read by two authors.
We used the following criteria for the inclusion and
exclusion of the articles
▸ No research design limit was used. However, letters to
the editors and abstract-only publications were
excluded;
▸ Studies that were directly relevant to ATM issues were
included. For example, for RUM studies, we consid-
ered studies that assessed RUM in a certain setting or
studies that sought to improve the use of medicines
speciﬁcally. However, broader studies of improving the
quality of clinical care (which might have involved pre-
scribing issues) were not included. (eg, a clinical
Figure 1 Flow chart of search strategies in electronic databases for access to and appropriate use of medicines.
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practice guideline development project may not be
included). Although prescribing is a part of the majority
of the guidelines, if the purpose of the guideline is not
prescribing per se; then the article may not be included
in here. This criterion was required to ensure that we
remained focused on ATM issues. The same logic was
applied to other aspects of ATM;
▸ Studies of drug resistance that did not elaborate on
the health system or ATM implications, studies of
herbal medicines alone, studies of drug misuse,
studies of use of contraceptive medicines that focused
on family planning issues only and studies focusing
only on education methods and curriculum develop-
ment for pharmacy courses were not included.
Data extraction and analysis
After agreeing on the inclusion of a study, the full texts of
the studies were retrieved. We developed a data extrac-
tion tool based on the study conceptual framework. We
extracted data on the title, authors, year of publication,
corresponding author’s country of origin, countries of
focus, research design and sample, summary of the main
ﬁndings, ATM issues considered in the study, ‘levels’ of
barrier studied and the research topics recommended by
the authors. If a publication discussed more than one
ATM issue, we noted as many issues as applied to that
publication.
We categorised the ‘levels’ of the health system barriers to
ATM as: ‘household and community’, ‘health service provi-
ders’, ‘health sector as a whole’, ‘other related sectors’ and
‘cross border issues’.11 12 We deﬁned ATM issues based on
the WHO Framework for ATM, which included four
aspects: affordability, sustainability of ﬁnancing, rational
use, and health systems and availability of medicines.13
One author extracted data from all the included studies,
and another author assessed all the data extractions for
accuracy and completeness. Then we used not only
descriptive methods and presentational graphs and dia-
grams pertaining to the study questions, but also Pearson r
estimates to assess the publication trends over time.
RESULTS
In total, 4755 titles were retrieved as a result of the
searches and were reviewed (ﬁgure 1). In total, 151
articles were identiﬁed (ﬁgure 1) that focused entirely
or partially on ATM issues in one or more of EMR’s
LMICs.
As the search strategy was sensitive to identify studies
that were conducted in LMICs, we also identiﬁed an
additional 12 international studies that had important
implications about ATM in LMICs of the region.1 14–24
Among these 12 studies, 8 had been published in 2011
alone. We used these studies to discuss and highlight
some of the identiﬁed issues but did not include them
in the analyses.
Six articles were published in languages other than
English: French (two each from Tunisia and Morocco
and one from Lebanon) and Czech (on Yemen).
Countries of origins of the studies
Most of these articles (117 articles, 77%) originated
(based on the corresponding author’s address) from the
LMICs in EMR, while eight (5%) originated from high-
income countries of the region and 26 (17%) from
other countries (ﬁgure 2A). There was a wide variation
in the number of publications per country (ﬁgure 2A).
The countries that produced at least 10 articles in the
journals indexed in international databases were Iran
(41, 27%), Pakistan (15, 10%), Jordan (13, 9%) and
Lebanon (10, 7%). These were followed by Sudan (9),
Palestine Occupied Territories (8), Egypt (6), the USA
(5) and Kuwait (5).
Figure 2 Distribution of the country of origin (A) and the country of focus* (B) for publications on access to and appropriate use
of medicines issues in the Eastern Mediterranean Region’s low-income and middle-income countries.
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We found several comparative international studies
that used data from EMR or discussed issues relevant
to EMR countries. In total, 17% of the identiﬁed lit-
erature originated from countries outside EMR.
Eleven (out of 26) of these studies were multicountry
studies that included one or more EMR countries
alongside others.
Countries of focus of the studies
In total, 14 EMR LMICs have been the focus of at least
one ATM research article in the past decade. The coun-
tries that were the focus of at least 10 articles were Iran
(46, 30%), Pakistan (28, 19%), Sudan (20, 13%), Jordan
(18, 12%) and Lebanon (16, 11%).
Two countries (Iraq, Libya) were discussed in only two
articles each (ﬁgure 2B). We found no studies on
Somalia and Djibouti. There were also no studies on
South Sudan, that is, none of the publications discussing
Sudan had speciﬁc attention or data from South Sudan,
which is now an independent country.
Research designs
The majority of the included studies involved cross-
sectional studies of various designs. Questionnaire
surveys—of facilities, providers and students (38 arti-
cles), patients and users (16 articles) and households (7
articles)—were the most common research designs and
were used in 41% of the articles. This was followed by
prescription audits and medicines utilisation reviews that
were observed in 35 articles (23%). Qualitative studies
(mainly as case studies) were observed in 10 articles.
Similarly, 15 articles (10%) focused on policy-related
issues in review articles, policy briefs or advocacy articles,
although pinpointing the research designs in these
studies was not straightforward and some studies did not
employ a formal research approach.
We also identiﬁed 13 interventional studies (including
2 randomised controlled trials), 2 economic studies and
2 consensus development studies. These articles, except
for one, were all published since 2008. We included
nine secondary data analyses (mostly involving multi-
national data analyses), one systematic review, one biblio-
metric study, one cohort and one case–control study.
The studies had substantial variations in their designs,
from well-designed trials or large-sample national and
multinational studies to small-scale studies of convenient
samples or with unclear research designs.
Growth in ATM publications
We observed a relatively steady growth in the number of
publications per year on ATM in EMR within the last
decade (Pearson r=0.87; see ﬁgure 3). While in the ﬁrst
3 years of this period there were only about 10 publica-
tions from the region, 80 studies had been published in
the last 3 years of the study period. We also observed a
modest increase in the proportion of studies originated
from outside EMR during the 2006–2010 period (20%)
compared with the 2000–2004 period (13%).
ATM issues of focus
To understand the ATM issues on which the published
article focused, we assigned each article to one or more
of the four large components in the WHO ATM frame-
work. We noted the ATM issues of focus for the articles:
affordability (25, 17%), ﬁnancing (18, 12%), rational
use (106, 70%), and health system and availability (63,
42%; table 1). RUM studies were the main bulk of the
studies conducted in the region, while very limited atten-
tion had been devoted to the ﬁnancing aspects of access
to medicines.
Similarly, the articles were assigned to one or more
‘health system levels’ that were the focus of attention for
the study (the total adds up to more than 151): house-
hold and community (44, 29%), health service (108,
72%), national health sector (79, 52%), national beyond
health sector (7, 5%) and cross border issues (9, 6%;
Figure 3 The increasing
number of access to and
appropriate use of medicines
publications per year and Eastern
Mediterranean Region. Note:
2011 publications cover only the
first half of this year.
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table 1). Despite the importance of cross-border issues
and the role of sectors beyond the health sector in facili-
tating or impeding ATM, scarce attention was devoted to
those issues in the region.
On the whole, the majority of the studies were limited
to the health services level, mainly assessing RUM issues
at the level of providers. We found many studies of avail-
ability and RUM issues (table 1), including studies that
focused on adverse drug reaction (ADR) reporting in
several countries.25 Many studies focused on reporting
simple RUM indicators for prescribing behaviours (eg,
average number of medicines per prescription, or the
proportion of prescriptions containing injectables), and
most reported an unfavourable picture.26–32 Others
focused on self-medication issues from different coun-
tries and areas and different subgroups of population.
The articles occasionally offered research recommen-
dations for future studies. Examples of such research
recommendations are offered in box 2.
As a further analysis, we focused attention on the
countries for which there were 10 or more ATM publica-
tions (Iran, Jordan, Lebanon, Pakistan and Sudan) to
see the proportion of these publications that discussed
different health system levels (table 2). Very few studies
considered cross-border issues and other relevant sectors
beyond the health sector. In terms of the ATM issues
considered in the studies, ATM research in Iran was
heavily biased towards RUM studies with 38 articles, fol-
lowed by health system issues (15 articles; table 2).
Other countries gave a more balanced picture, albeit
with a smaller number of articles: 9–13 articles on RUM,
6–14 articles on the health system and availability issues,
and 3–10 articles on affordability issues. Similarly, in all
ﬁve countries, the health service and national health
sector levels of the health system had attracted the
majority of the published ATM articles.
DISCUSSION
The results of the study showed that in 16 LMICs (now
17 countries including South Sudan) in EMR, with a
total population of over 537 million people, 151 articles
were published that focused entirely or in some parts on
ATM issues. These studies focused on 14 countries with
no publications assessing ATM issues in Djibouti,
Somalia or South Sudan. The countries that produced
Box 2 A few examples of research recommendations for
future studies reported in the included articles
▸ The cost-effectiveness of different respiratory care services on
tuberculosis case detection and health system strengthening33
▸ The cost-effectiveness of using community health workers or
outreach clinics for dispersed rural populations34
▸ The effect of various policy interventions to make medicine
more affordable7
▸ The impact of the national pharmaceutical policies on the
financial capacity of health systems, out-of-pocket health
expenditure and the domestic pharmaceutical industry35
▸ Identifying valid indicators for the assessment of physicians’
prescribing performance36
▸ The outcomes of unnecessary ‘stat’ (urgent) prescribing
orders on adverse drug events in hospitals37
▸ Using longer term routine data to assess the effects of essen-
tial medicines lists and universal health coverage policies on
rational use of medicines, out-of-pocket health expenditures
and health outcomes38
▸ The impact of legislative and market changes to improve the
quality of retail pharmacy in low-income and middle-income
countries39
▸ Formulating clinical guidelines for use of benzodiazepines in
different indications40
▸ The effectiveness of policies to improve access to medicines
in resource-poor countries based on research evidence from
such countries41
Table 1 ATM issues and health system levels discussed each year in EMR publications*
Year Affordability
Sustainable
financing RUM
Health
system and
availability
Household
and
community
Health
service
public or
private
National
health
sector
National
beyond
health
sector
Cross-border
issues
2000 2 1 2
2001 1 1 2 1 2 1
2002 1 1 5 3 3 2
2003 1 2 2 2
2004 2 1 2 2 1 2 2 1 1
2005 10 1 4 8 8
2006 2 8 5 3 10 5 2 1
2007 1 1 8 6 3 6 8 1
2008 4 5 16 9 9 18 13 1
2009 7 7 20 15 9 22 16 1 1
2010 4 20 10 6 20 14 1 1
2011 3 3 13 10 5 13 8 2 3
Total 25 18 106 63 44 108 79 7 9
*The totals add up to more than 151 as an article might be assigned to more than one ATM issue or health system level.
ATM, access to and appropriate use of medicines; EMR, Eastern Mediterranean Region; RUM, rational use of medicines.
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the most publications were Iran, Pakistan, Jordan and
Lebanon.
The number of publications for some countries was
proportionately very low. For example, if we had
excluded the studies from Egypt that were published
because of the presence of the WHO regional ofﬁce in
Cairo, then very few studies from Egypt would have
remained in our sample. This was surprising given that
Egypt is one of the most populous countries in the
region which enjoys an expanded academic sector.
The last decade demonstrates a growth in the number
of publications per year on ATM in EMR. This is a good
sign that with the further development of health
systems, the number of publications is growing. This may
provide a good opportunity for evidence-based decision-
making based on evidence from the region.42 However,
the publications were focused mainly on RUM issues
and most studies only assessed challenges at the service
provider level.43 There was limited attention to afford-
ability and ﬁnancing issues in the EMR region, and the
impact of cross-border factor and sectors other than the
health sector on ATM were rarely studied.
Lack of attention to the ﬁnancing and affordability
aspects of ATM in EMR studies is despite the fact that
several studies have demonstrated the importance of these
aspects.7 In an international study using household survey
data from the World Health Surveys, it was clear that
affordability was a major barrier to access at the level of
households. The study concluded that between 41% and
56% of households in LMICs spent almost all of their
healthcare expenditures on medicines.44 The study called
for expanded beneﬁt packages and further coverage of
medicines in insurance plans in low-income and lower
middle-income countries. Whether or not this was taken
up in the EMR region is another matter. Among the
LMICs in the region, Jordan, Iran, Egypt, Morocco and
Tunisia have healthcare insurance systems developed and
established by the government.45 46 These schemes have
varied successes and limitations that may impede access to
medicines.47 Despite this system’s development in these
countries, still limited attention to insurance-related issues
was observed in the ATM publications. For other LMICs
in the region, without such nationally funded pro-
grammes, it will be more difﬁcult to adopt and implement
Wagner et al’s44 advice.
Another issue for the affordability as well as ﬁnancing
of medicines in LMICs is the pricing of medicines.43
Wagner et al noted that there was an array of reasons
and manifestations of price differences for medicines in
different countries. Despite the importance of the issue,
they noted that the literature from developing countries
has shown very little attention to pricing issues.14 Our
ﬁndings support their conclusion.
The over-representation of RUM studies might be
linked to the availability of widely used instruments to
measure RUM, developed by the WHO and other organi-
sations. For example, the “investigating medicine use”
tools have existed since the early 1980s. Although in its
current edition it covers all areas of ATM,48 its original
versions paid special attention to the measurement of
RUM aspects of medicine. Pricing and availability tools
(WHO-HAI project) have been developed more
recently.49 Also, recently growing attention on ﬁnancing
mechanisms and universal health coverage seems to be
slowly attracting attention to these aspects applied to the
area of medicines. Note also that the standard household
survey and healthcare utilisation tools (eg, the World
Health Survey tool) that usually allow one to look at
health ﬁnancing aspects or out-of-pocket expenditures
often do not discriminate between medicines and other
items of expenditure. To assess households’ pharmaceut-
ical expenditure, primary data collection is usually
needed, which may be expensive and time consuming
and therefore limited only to countries that have the
resources to conduct such studies. Also, it seems that the
indicators and instruments on RUM are more widely
accepted than pricing indicators, for example, there may
be disagreement on measuring retail price, procurement
price, with or without mark-up.7 50 Still, one might hope
that with the emergence of further attention and better
tools to assess the ﬁnancing aspects of ATM, more articles
will be published on such issues in the near future.
Table 2 Distribution of the levels of barriers or issues considered in the ATM publications* in five countries with at least 10
publications†
Levels of barriers considered ATM issues considered
Household
and
community
Health
service
public or
private
National
health
sector
National
beyond
health
sector
Cross-border
issues Affordability
Sustainable
financing RUM
Health
system and
availability
Iran 12 33 25 3 3 6 6 38 15
Jordan 6 14 9 0 0 3 2 10 9
Lebanon 3 14 9 0 0 4 2 9 10
Pakistan 7 21 15 3 4 10 5 13 14
Sudan 6 16 11 1 1 6 4 13 6
*Each article may have considered more than one barrier or issue.
†The numbers are based on the country of focus of the publications.
ATM, access to and appropriate use of medicines.
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RUM research in the region has been mainly in the
shape of prescription audits, the majority of it showing
that there are important problems in prescrip-
tions.32 43 51–53 There are two important patterns to note
in here. First, the RUM research, although forming the
majority of ATM research, is yet to show a substantial
effect in improving the drug utilisation patterns. The
prescribing problems of focus that existed 10 years ago
remain unresolved today, if not joined by new challenges
(eg, non-generic prescribing). For example, one study
that assessed ADR repots for artemisinin-based antimal-
arial treatments did not ﬁnd a single report of ADR for
artemisinin-based medicines from EMR countries with
hyperendemic and mesoendemic malaria problems.54
Also, studies of pharmacy service quality demonstrated a
low quality of service and a room for improvement in
provision of care at the pharmacies.55 In a way, maybe it
is safe to conclude that even RUM studies have not been
that effective in improving access, or in tackling the
main issues.
Second, it seems that a change in research strategies
is required and future studies should focus further on asses-
sing the impacts of relevant interventions. Fortunately, in
recent years, there is a shift towards interventional studies
assessing the impact of interventions on improving prescrib-
ing outcomes.33 56–59 Also, further demand side (eg, why
the public still seems to be fascinated with antibiotics),
supply side (eg, how physicians might be encouraged to
follow evidence-based prescribing) and health systems
angle (eg, what are the ﬁnancial and organisational barriers
to improving prescribing patterns) research is required.
Other sectors’ (other than the healthcare sector)
effects on access to medicines are barely considered in
the publications from the region. Studies have generally
demonstrated that the general socioeconomic status of a
country is linked to ATM, while a few studies have elabo-
rated on this in the region.60 Despite the numerous
studies that assessed the impact of the health system and
provision issues on ATM, there are very few studies that
discuss important policy directions for improving ATM.
For example, we did not ﬁnd any study that had assessed
the impact of essential drug list initiatives on access to
medicines in an EMR country. This is despite the fact
that, according to Mirza,45 all the LMICs in the EMR
region, except Libya and Lebanon, had a policy of
essential drug lists in place at the time.
Ritz and Laing41 reported the ﬁndings of a bibliomet-
ric study of ATM literature in LMICs. Compared with
our study, they underestimated the number of articles
produced from the EMR region by a wide margin. They
suggested that medicine selection, intellectual property
rights and monitoring and quality assurance were
among the top ATM topics studied in developing coun-
tries, which is different from what we observed in EMR.
Interestingly, Ritz and Laing observed that the corre-
sponding authors residing in high-income countries
represented around 50% of all publications relative to
LMICs. Our study demonstrated that most articles
(77%) in the region originated (as per the correspond-
ing author’s address) from LMICs in the region.
There are several limitations to the current bibliog-
raphy study. Using the afﬁliation of the corresponding
author to identify the study’s country of origin has
several limitations. For example, it may be teamwork, in
which case authors from different countries contribute.
Also, several identiﬁed studies were from research stu-
dents in high-income countries’ institutions running
research in their own countries. Many such students are
also funded by their own countries, but may use the
afﬁliations of the institutions in which they study. On the
other hand, there are studies conducted by foreign mis-
sions based in a country, and although the address of
the foreign mission is from that country, the study
cannot be strictly considered as home-grown. Despite
such limitations, the bibliographic reviews are inform-
ative of a country’s productivity in ATM research.
We conducted systematic searches of the main inter-
national databases for identifying ATM articles. Although
we followed rigorous methods, the search should not be
considered exhaustive. We might have missed published
articles not indexed in these databases. However, as most of
the important health research from the region makes it to
international databases, we believe that we have captured a
substantial number, if not the majority, of articles on ATM.
CONCLUSIONS
The provision of reliable access to affordable, appropri-
ate and high-quality medicines is a key component of a
functioning health system. Access to medicines needs to
be fully integrated with health ﬁnancing, human
resource planning, service delivery, information and gov-
ernance systems. This is the ﬁrst study conducted in this
region that has collated the published literature and
summarised the main policy concerns to identify ATM
research priorities. In this study, we used an extensive
search of the local and regional literature. We developed
detailed maps of research on the issue, conceptual fra-
meworks of policy concerns and issues and identiﬁed
lists of ATM research priorities for the countries of focus
and the region as a whole.
This study clearly indicates that there is dire need for
further research on the ﬁnancing and affordability
aspects of ATM in the region. This should be given para-
mount attention in future research funding and calls for
proposals. Also, cross-border issues and other sectors’
roles on access to medicines in the region have not been
explored widely. It seems that many household (demand
side) studies in the region continue to be of poor
quality and limited methods. Together, these main areas
should provide the main aspects of access to medicines
research in the region.
This does not in any way indicate that further RUM or
studies of health systems and availability access are not
needed, or that the barriers at the levels of providers
and health systems are exhaustively identiﬁed. Rather, it
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seems that individual researchers and the available
funding route are paying attention to these issues at the
moment, which should continue while further resources
should be mobilised for studies related to the relatively
ignored aspects of ATM research in the region.
The picture of research on ATM in the region is
better than what had been reported in recent publica-
tions41 or compared with other regions.6 There is a
growing trend, over the years, of more and better quality
studies from the region appearing in international jour-
nals. Still, a concurrent trend will be required to ensure
that the local audience of such research (ie, practi-
tioners, policymakers and media) remains informed of
the new development as a result of ATM research in
countries in the region. An active knowledge translation
approach will be essential.
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